Published Date: 13 Mar 2023
Italy: Treatment with SGLT2 inhibitors in patients with type 2 diabetes (T2D) is associated with a reduced risk of restenosis in the stent...
Read Full NewsAt CTAD 2025, the chief scientific officer at the Banner Alzheimer’s Institute discussed emerging antiamyloid therapies, clinical trial insights, and treatment duration in Alzheimer disease.
New data highlights neflamapimod's potential in reducing biomarkers and improving clinical outcomes for dementia with Lewy bodies, paving the way for Phase 3 trials.
Semaglutide shows no significant impact on Alzheimer disease progression in large trials, despite some biomarker improvements and consistent safety profiles.
In a study presented at CTAD 2025, patients treated with lecanemab showed a 59% increase in cerebrospinal fluid protofibril concentration at 12 months and a 45% increase at 18 months.
A groundbreaking phase 1 trial reveals promising results for a new stem cell therapy targeting Alzheimer disease, advancing to phase 2 studies.
Recurrent UTIs Linked to QOL Burden in Kidney Transplant Recipients
1.
Addition of regional nodal irradiation does not decrease rates of invasive breast cancer recurrence, study finds
2.
Increased anti-tumor response and reduced side effects from immune checkpoint inhibitors.
3.
UK study evaluates effectiveness of cancer diagnosis pathway for patients with non-specific symptoms
4.
New PET tracer enables same-day imaging of triple-negative breast and urothelial cancers
5.
First-Line Combination for Bladder Cancer Not Eligible for Cisplatin Just Misses Positive Outcome.
1.
Demystifying Hypereosinophilic Syndrome: Symptoms, Diagnosis, and Treatment Options
2.
Can Wearables and AI Become a Gamechanger for Histiocytic Cancer Detection?
3.
Understanding Odontogenic Keratocyst: Symptoms, Causes, and Treatments from Dental Experts
4.
Unveiling the Mysteries of Smudge Cells: A New Frontier in Cellular Biology
5.
AI-Driven Chemotherapy: Transforming Cancer Care with Precision and Efficiency
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Navigating the Complexities of Ph Negative ALL - Part III
2.
Incidence of Lung Cancer- An Overview to Understand ALK Rearranged NSCLC
3.
Role of Nimotuzumab in Management of Nasopharyngeal Cancer
4.
Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in MRD Negativity
5.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VI
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation